Audentestherapeutics

Developer of therapeutics to treat rare genetic diseases

placeSan Francisco, California, United States calendar_todayFounded 2013 groups404 employees language audentestx.com

Registered entities

Investor mix

17 investors on record; lead investors include Deerfield Triarc Capital, Sofinnova Investments, Redmile Group; 1 has since exited.

Investor typeCountShare
Venture capital847%
Private equity212%
Bank & private debt318%
Other / undisclosed424%
Coming soon